Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VERA
STRONG SELLVera Therapeutics, Inc. · Healthcare · United States · $2.5B · Avg Vol: $79M/d
COMPANY DESCRIPTION
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for patients with serious immunological and inflammatory diseases. The company's competitive moat is derived from its pipeline of differentiated drug candidates, particularly its lead asset for IgA nephropathy, addressing conditions with high unmet medical needs. Vera Therapeutics aims to deliver transformative treatments for autoimmune diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 32.1M | 261.1M | — |
| EPS | -1.30 | -2.25 | -2.75 | -4.66 | — | -5.33 | -6.21 | -3.86 | — |
| Shares | 71.8M | 44.5M | 63.6M | 71.3M | -0.7% | 71.8M | — | — | — |
| Debt | 31.3M | 53.7M | 54.6M | 77.3M | 35.2% | 76.9M | — | — | — |
| Equity | 76.9M | 101.7M | 577.2M | 604.5M | 98.8% | — | — | — | — |
| Op CF | -67.6M | -92.2M | -134.7M | -241.1M | — | -293.2M | — | — | — |
| Inv CF | -70.6M | -39.4M | -425.0M | 194.3M | — | — | — | — | — |
| Fin CF | 101.9M | 133.5M | 606.7M | 308.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VERA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VERA | Vera Therapeutics, Inc.(you) | $2.5B | 9 | STRONG SELL |
| KLRA | Kailera Therapeutics, Inc. | $2.3B | 9 | STRONG SELL |
| OCUL | Ocular Therapeutix, Inc. | $1.9B | 9 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
| KARD | Kardigan, Inc. | $1.9B | 8 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 16 | STRONG SELL |
| BEAM | Beam Therapeutics Inc. | $2.6B | 17 | STRONG SELL |
| GENB | Generate Biomedicines, Inc. | $1.7B | 8 | STRONG SELL |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | 3 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%